🚀 VC round data is live in beta, check it out!
Jiangsu Bioperfectus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiangsu Bioperfectus and similar public comparables like Assure Tech, Castle Biosciences, Lunit, Integral Diagnostics and more.
Jiangsu Bioperfectus Overview
About Jiangsu Bioperfectus
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Founded
2010
HQ
Employees
N/A
Website
Financials (FY)
EV
$525M
Jiangsu Bioperfectus Financials
Jiangsu Bioperfectus reported last fiscal year revenue of $51M and EBITDA of $10M.
In the same fiscal year, Jiangsu Bioperfectus generated $32M in gross profit, $10M in EBITDA, and had net loss of ($293K).
Jiangsu Bioperfectus P&L
In the most recent fiscal year, Jiangsu Bioperfectus reported revenue of $51M and EBITDA of $10M.
Jiangsu Bioperfectus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $51M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $32M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 62% | XXX | XXX | XXX |
| EBITDA | — | XXX | $10M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (11%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($293K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (1%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jiangsu Bioperfectus Stock Performance
Jiangsu Bioperfectus has current market cap of $701M, and enterprise value of $525M.
Market Cap Evolution
Jiangsu Bioperfectus' stock price is $8.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $525M | $701M | 7.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiangsu Bioperfectus Valuation Multiples
Jiangsu Bioperfectus trades at 10.2x EV/Revenue multiple, and 50.7x EV/EBITDA.
Jiangsu Bioperfectus Financial Valuation Multiples
As of April 18, 2026, Jiangsu Bioperfectus has market cap of $701M and EV of $525M.
Equity research analysts estimate Jiangsu Bioperfectus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Bioperfectus has a P/E ratio of (2388.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $701M | XXX | $701M | XXX | XXX | XXX |
| EV (current) | $525M | XXX | $525M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 50.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (93.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 16.5x | XXX | XXX | XXX |
| P/E | — | XXX | (2388.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 43.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiangsu Bioperfectus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jiangsu Bioperfectus Margins & Growth Rates
Jiangsu Bioperfectus' revenue in the last fiscal year declined by (13%).
Jiangsu Bioperfectus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (124%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jiangsu Bioperfectus Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jiangsu Bioperfectus | XXX | XXX | XXX | XXX | XXX | XXX |
| Assure Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Castle Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Lunit | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnósticos da América | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Bioperfectus M&A Activity
Jiangsu Bioperfectus acquired XXX companies to date.
Last acquisition by Jiangsu Bioperfectus was on XXXXXXXX, XXXXX. Jiangsu Bioperfectus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jiangsu Bioperfectus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJiangsu Bioperfectus Investment Activity
Jiangsu Bioperfectus invested in XXX companies to date.
Jiangsu Bioperfectus made its latest investment on XXXXXXXX, XXXXX. Jiangsu Bioperfectus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jiangsu Bioperfectus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiangsu Bioperfectus
| When was Jiangsu Bioperfectus founded? | Jiangsu Bioperfectus was founded in 2010. |
| Where is Jiangsu Bioperfectus headquartered? | Jiangsu Bioperfectus is headquartered in China. |
| Is Jiangsu Bioperfectus publicly listed? | Yes, Jiangsu Bioperfectus is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Jiangsu Bioperfectus? | Jiangsu Bioperfectus trades under 688399 ticker. |
| When did Jiangsu Bioperfectus go public? | Jiangsu Bioperfectus went public in 2019. |
| Who are competitors of Jiangsu Bioperfectus? | Jiangsu Bioperfectus main competitors are Assure Tech, Castle Biosciences, Lunit, Integral Diagnostics. |
| What is the current market cap of Jiangsu Bioperfectus? | Jiangsu Bioperfectus' current market cap is $701M. |
| What is the current revenue of Jiangsu Bioperfectus? | Jiangsu Bioperfectus' last fiscal year revenue is $51M. |
| What is the current EV/Revenue multiple of Jiangsu Bioperfectus? | Current revenue multiple of Jiangsu Bioperfectus is 10.2x. |
| Is Jiangsu Bioperfectus profitable? | No, Jiangsu Bioperfectus is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.